AstraZeneca ups the ante in EGFR race with Clovis
This article was originally published in Scrip
AstraZeneca and Clovis Oncology are neck-and-neck in the race to bring next-generation epidermal growth factor receptor (EGFR) inhibitors to the market for lung cancer, but AstraZeneca may one-up Clovis with a new drug application (NDA) submission to the US FDA in the first quarter of 2015.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.